HUMAWNMS

Humacyte, Inc.

-21.7% · 90d

$0.08

-0.01 (-7.83%)

News

No News Yet

Press releases and SEC filings for HUMAW will appear here as they are published.

Check back later for updates

Key Data

Market Cap—

Open$0.23

Prev Close$0.09

Day Range$0.07 – $0.08

52W Range$0.07 – $0.08

Volume10,065

P/E (TTM)—

EPS$-3.16

Dividend Yield—

Beta2.10

About

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.

184 employees

www.humacyte.com

Top Institutional Holders

As of 2025-12-31 · prior 2025-09-30

BlackRock, Inc.$10.9M

11,345,119 sh+14.6%

VANGUARD GROUP INC$8.1M

8,416,971 sh+11.9%

GEODE CAPITAL MANAGEMENT, LLC$3.6M

3,720,436 sh+20.2%

Woodline Partners LP$1.9M

2,002,073 sh0.0%

STATE STREET CORP$2.7M

2,837,276 sh+17.8%

See all holders →

Quarterly Financials

09/25

Revenue Net Income